Drug evaluation: AMG-531 for the treatment of thrombocytopenias.

Abstract

Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

• Authors: Lawrence Rice
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 9 Pg. 834-41 (Sep 2006) ISSN: 1472-4472 [Print] England
• PMID: 17002262 (Publication Type: Journal Article, Review)

Chemical References

• Carrier Proteins
• Receptors, Fc
• Recombinant Fusion Proteins
• Thrombopoietin
• romiplostim

Topics

• Animals
• Carrier Proteins (adverse effects, chemical synthesis, metabolism, pharmacokinetics, pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Humans
• Quantitative Structure-Activity Relationship
• Receptors, Fc (metabolism, therapeutic use)
• Recombinant Fusion Proteins
• Thrombocytopenia (drug therapy)
• Thrombopoietin